// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Exploring respiratory rate as a novel health marker in COPD

Grace France - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Urinary metabolomics-profiling of the U-BIOPRED asthma study identified biochemical clusters associated with asthma severity

Craig Wheelock - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

The SAQ is a valid quality of life measure in severe asthma: the mini-AQLQ and ACQ both measure symptoms

Matthew Masoli - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Comparison of two published definitions of sputum neutrophilia show clinical measures of disease are more severe in neutrophilic asthma (NA than non-neutrophilic asthma (NNA using >40% sputum neutrophils as the definition of disease

Clair Barber - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Definition of COPD phenotype depending on eosinophil count

Markus Polke - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Clinical prognostic tools and their use in COPD

Nicholas Lane - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Feasibility of daily vital signs monitoring (VSM in COPD

Grace France - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

How can we improve availability of quality assured spirometry for patients admitted with an exacerbation of COPD?

Ciaran Mooney - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Frailty and Risk of COPD Readmission within 30 Days Following Exacerbation of COPD

Jaber Alqahtani - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

A systematic review of the use of physiological tests assessing the acute response to treatment during exacerbations of COPD

Nowaf Alobaidi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Normative data across the age range for Multiple Breath Nitrogen Washout

Katherine O'Neill - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pneumothorax

N/A

Automated telephone message service for people with uncontrolled asthma or COPD

Jayne Longstaff - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

The 'surprise question' in patients surviving severe COPD exacerbation

Sarah Gillespie - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Analysis of NEWS2 trend to predict risk of death in COPD

Sarah Forster - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effect of smoking cessation on CT imaging in patients with COPD: a systematic review

Daryl Cheng - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

High healthcare utilisation and functional impairment in inducible laryngeal obstruction: results from the UK national registry

Jemma Haines - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Within-day repeatability of fractional exhaled nitric oxide in severe asthma

Ran Wang - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Changes in exhaled breath particles lipid composition following experimental endotoxin challenge

Olaf Holz - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

LT 02

Impact of PAHs exposure on exacerbation frequency in asthma using a new grid-scale simulation of PM2.5-PAHs distribution

Te Fang Sheng - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Mode of delivery and lung function of 16-19 year olds born at less than 29 weeks gestation

Christopher Harris - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved